Form 4: Cencora CEO Mauch Reports Equity Transactions

Cencora's President & CEO, Robert P. Mauch, reported the acquisition of common stock from performance share units and a new grant of restricted stock units, alongside a sale for tax withholding.

Summary

• Robert P. Mauch, President & CEO and Director of Cencora, Inc. (COR), reported changes in his beneficial ownership of company securities.
• Acquired 42,944 shares of common stock on November 13, 2025, for no consideration, resulting from the satisfaction of performance criteria for performance share units.
• Disposed of 18,677 shares of common stock on November 13, 2025, at a price of $312.53 per share, to satisfy tax withholding obligations related to the vesting of performance share units.
• Beneficial ownership of common stock following these transactions is 67,079 shares.
• Received a grant of 15,960 Restricted Stock Units (RSUs) on November 12, 2025, for no consideration.
• These RSUs will vest in three equal installments on November 12, 2026, November 12, 2027, and November 12, 2028.
• Beneficial ownership of derivative securities (RSUs) following this transaction is 15,960 units.

Sentiment

Score: 6

Explanation: The filing reports routine executive compensation events, including the vesting of performance share units and a new grant of restricted stock units, alongside a disposition for tax withholding. These transactions are standard for executive incentive plans and do not indicate a significant shift in company fundamentals or management's outlook.

Positives

• Acquisition of 42,944 shares of common stock for no consideration, indicating successful achievement of performance criteria for existing performance share units.
• Grant of 15,960 Restricted Stock Units (RSUs) aligns executive incentives with long-term shareholder value and promotes retention.

Negatives

• Disposition of 18,677 shares of common stock to cover tax withholding obligations, which is a reduction in direct share ownership, albeit for a routine purpose.

Future Outlook

The grant of Restricted Stock Units with vesting dates extending to November 2028 indicates a long-term retention strategy for the President & CEO, aligning future compensation with sustained company performance.

Industry Context

These types of equity grants, including performance share units and restricted stock units, are standard components of executive compensation packages across various industries, including pharmaceuticals and healthcare services. They aim to align management incentives with long-term shareholder value and are a common practice for retaining key executives.

Comparison to Industry Standards

• Executive compensation structures, particularly the use of performance-based equity and restricted stock units, are consistent with common practices observed in large publicly traded companies within the healthcare distribution and pharmaceutical sectors.
• Similar compensation strategies are employed by peers like Cardinal Health (CAH) and McKesson Corporation (MCK) to incentivize leadership and ensure retention, reflecting an industry-standard approach to executive remuneration.

Stakeholder Impact

• Shareholders: The equity grants align the interests of the President & CEO with long-term shareholder value creation.
• Employees: Standard executive compensation practices can influence overall company compensation philosophy and morale.

Next Steps

• The granted Restricted Stock Units will vest in three equal installments on November 12, 2026, November 12, 2027, and November 12, 2028.

Key Dates

Keywords

Cencora, COR, Robert P. Mauch, Insider Trading, Form 4, Equity Transactions, Performance Share Units, Restricted Stock Units, CEO, Director, Executive Compensation